Hepatitis C is a virus that infects the liver, often silently, sometimes causing serious damage over years or decades without any obvious warning signs. An estimated 50 million people worldwide are living with chronic hepatitis C, with about 1 million new infections each year. The good news: modern treatments now cure more than 95% of cases.
How Hepatitis C Works in the Body
Hepatitis C virus (HCV) is a small, enveloped virus that carries its genetic instructions on a single strand of RNA. It belongs to the same broad family as dengue and Zika viruses, though it behaves very differently. Once it enters the bloodstream, HCV targets liver cells, hijacking their machinery to replicate. The immune system often struggles to eliminate it because the virus mutates rapidly, essentially changing its disguise faster than the body can keep up.
There are multiple genetic variants, called genotypes. Genotype 1 is the most common worldwide, responsible for about 44% of infections. Genotype 3 accounts for roughly 25%. These distinctions used to matter a great deal for treatment, but current medications work well against all of them.
How It Spreads
Hepatitis C spreads through blood-to-blood contact. The most common route today is sharing needles or other equipment used to inject drugs. Before widespread blood supply screening began in the early 1990s, transfusions and organ transplants were a significant source of infections. That risk is now extremely small in countries with modern screening programs.
Other less common routes include needlestick injuries in healthcare settings, getting tattoos or piercings with improperly sterilized equipment, and sharing personal items like razors or toothbrushes that may carry trace amounts of blood. Sexual transmission is possible but uncommon, with the risk increasing when blood is present. A mother can also pass the virus to her baby during childbirth, though this happens in a minority of cases. Hepatitis C does not spread through casual contact, hugging, sharing food, or breastfeeding.
Acute vs. Chronic Infection
Hepatitis C infection unfolds in two phases. The acute phase covers the first six months after exposure. During this window, some people’s immune systems successfully fight off the virus on their own. But that outcome is the exception, not the rule. An estimated 55 to 85% of people who contract HCV develop a chronic infection, meaning the virus persists in their body beyond six months.
Chronic hepatitis C is where the real danger lies. Over years or decades, the virus gradually damages liver cells, triggering inflammation and scarring (fibrosis). If that scarring progresses far enough, it becomes cirrhosis, a condition where the liver can no longer function properly. Chronic infection also increases the risk of liver cancer. The timeline varies widely from person to person. Some people live with the virus for 20 or 30 years before significant liver damage develops, while others progress faster, especially if they drink alcohol heavily or carry other liver conditions.
Why Most People Don’t Know They Have It
Hepatitis C is often called a “silent” infection for good reason. Most people with hepatitis C have no symptoms at all. When symptoms do appear during the acute phase, they typically show up 2 to 12 weeks after exposure, though the range can stretch to 26 weeks. Even then, the symptoms tend to be mild and vague enough that people chalk them up to a flu or general fatigue.
Possible symptoms include:
- Fatigue and general feeling of illness
- Loss of appetite, nausea, or vomiting
- Abdominal pain
- Joint or body aches
- Fever
- Dark urine or pale, clay-colored stool
- Jaundice (yellowing of the skin or whites of the eyes)
Many people with chronic hepatitis C feel completely fine for years, even as liver damage accumulates quietly. This is why screening matters so much. The CDC recommends that all adults aged 18 and older get tested at least once in their lifetime.
How Hepatitis C Is Diagnosed
Testing for hepatitis C is a two-step process, and both steps can often be done from blood drawn in a single visit. The first test checks for antibodies, proteins your immune system produces in response to the virus. A positive antibody result means you’ve been exposed to hepatitis C at some point, but it doesn’t tell you whether the virus is still active. People who cleared the infection on their own, or were cured through treatment, will still test positive for antibodies.
If the antibody test comes back positive, a second test looks for the virus’s actual genetic material (HCV RNA) in your blood. This is the test that confirms a current, active infection. Many labs now run the second test automatically when the antibody result is positive, so you may get a definitive answer without needing a separate appointment.
Treatment and Cure Rates
Hepatitis C is one of the few chronic viral infections that can be completely cured. The current standard of care involves direct-acting antiviral medications, which are taken as pills, typically for 8 to 12 weeks. These drugs work by blocking specific steps the virus needs to reproduce inside liver cells.
The cure rates are remarkably high. In a large analysis of over 40,000 people treated with these medications, 96.8% were cured. Cure rates above 95% hold true regardless of which genotype someone carries, how much virus is in their blood, their race, whether they also have HIV, or even whether they’ve already developed significant liver scarring. “Cured” in this context means the virus is undetectable in the blood 12 weeks after finishing treatment. Once that milestone is reached, the infection does not come back on its own, though reinfection through new blood-to-blood exposure is possible.
Treatment is generally well tolerated. Side effects tend to be mild, with fatigue and headache being the most commonly reported. This is a dramatic improvement over older treatments, which lasted up to a year, involved injections, and caused significant side effects while curing only about half of patients.
No Vaccine Exists Yet
Unlike hepatitis A and B, there is no vaccine for hepatitis C. The virus’s rapid mutation rate makes it a difficult target. Vaccine candidates are in development, but none have reached the point of being available to the public. The same genetic variability that helps the virus evade the immune system also makes it hard to design a vaccine that provides broad, lasting protection.
Without a vaccine, prevention relies on avoiding blood-to-blood contact with an infected person. For people who inject drugs, using clean needles and not sharing equipment is the most effective way to reduce risk. Healthcare workers should follow standard precautions around needles and sharp instruments. If you’re getting a tattoo or piercing, verify that the facility uses sterile, single-use equipment.